These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 39192322)

  • 1. Systematic assessment of HER2 status in ductal carcinoma in situ of the breast: a perspective on the potential clinical relevance.
    Van Bockstal MR; Wesseling J; Lips EH; Smidt M; Galant C; van Deurzen CHM
    Breast Cancer Res; 2024 Aug; 26(1):125. PubMed ID: 39192322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of subsequent in situ and invasive breast cancer in human epidermal growth factor receptor 2-positive ductal carcinoma in situ.
    Curigliano G; Disalvatore D; Esposito A; Pruneri G; Lazzeroni M; Guerrieri-Gonzaga A; Luini A; Orecchia R; Goldhirsch A; Rotmensz N; Bonanni B; Viale G
    Ann Oncol; 2015 Apr; 26(4):682-687. PubMed ID: 25600567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study.
    Borgquist S; Zhou W; Jirström K; Amini RM; Sollie T; Sørlie T; Blomqvist C; Butt S; Wärnberg F
    BMC Cancer; 2015 Jun; 15():468. PubMed ID: 26062614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast.
    Barnes NL; Khavari S; Boland GP; Cramer A; Knox WF; Bundred NJ
    Clin Cancer Res; 2005 Mar; 11(6):2163-8. PubMed ID: 15788662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Relationships between HER2 Overexpression and DCIS Characteristics.
    Di Cesare P; Pavesi L; Villani L; Battaglia A; Da Prada GA; Riccardi A; Frascaroli M
    Breast J; 2017 May; 23(3):307-314. PubMed ID: 27943525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Possible Prognostic Role of HER2/Neu in Ductal Carcinoma In Situ and Atypical Ductal Proliferative Lesions of the Breast.
    Daoud SA; Ismail WM; Abdelhamid MS; Nabil TM; Daoud SA
    Asian Pac J Cancer Prev; 2016; 17(8):3733-6. PubMed ID: 27644608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clonal alteration of breast cancer receptors between primary ductal carcinoma in situ (DCIS) and corresponding local events.
    Karlsson E; Sandelin K; Appelgren J; Zhou W; Jirström K; Bergh J; Wärnberg F
    Eur J Cancer; 2014 Feb; 50(3):517-24. PubMed ID: 24275214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hormonal receptor status, Ki-67 and HER2 expression: Prognostic value in the recurrence of ductal carcinoma in situ of the breast?
    Poulakaki N; Makris GM; Battista MJ; Böhm D; Petraki K; Bafaloukos D; Sergentanis TN; Siristatidis C; Chrelias C; Papantoniou N
    Breast; 2016 Feb; 25():57-61. PubMed ID: 26612082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Expression of fatty acid synthase and its association with HER2 in invasive ductal carcinoma of breast].
    Yang M; Xu SP; Ao QL
    Zhonghua Bing Li Xue Za Zhi; 2013 Apr; 42(4):257-61. PubMed ID: 23928534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of HER2 amplification status among breast cancer subgroups offers new insights in pathways of breast cancer progression.
    Lambein K; Van Bockstal M; Vandemaele L; Van den Broecke R; Cocquyt V; Geenen S; Denys H; Libbrecht L
    Virchows Arch; 2017 Nov; 471(5):575-587. PubMed ID: 28567637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is there a low-grade precursor pathway in breast cancer?
    King TA; Sakr RA; Muhsen S; Andrade VP; Giri D; Van Zee KJ; Morrow M
    Ann Surg Oncol; 2012 Apr; 19(4):1115-21. PubMed ID: 21935747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry.
    Park K; Han S; Kim HJ; Kim J; Shin E
    Histopathology; 2006 May; 48(6):702-7. PubMed ID: 16681686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subtypes of high-grade breast ductal carcinoma in situ (DCIS): incidence and potential clinical impact.
    Schandiz H; Park D; Kaiser YL; Lyngra M; Talleraas IS; Geisler J; Sauer T
    Breast Cancer Res Treat; 2023 Sep; 201(2):329-338. PubMed ID: 37453021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HER2/neu and Ki-67 expression predict non-invasive recurrence following breast-conserving therapy for ductal carcinoma in situ.
    Rakovitch E; Nofech-Mozes S; Hanna W; Narod S; Thiruchelvam D; Saskin R; Spayne J; Taylor C; Paszat L
    Br J Cancer; 2012 Mar; 106(6):1160-5. PubMed ID: 22361634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Her2 and Ki67 Biomarkers Predict Recurrence of Ductal Carcinoma in Situ.
    Davis JE; Nemesure B; Mehmood S; Nayi V; Burke S; Brzostek SR; Singh M
    Appl Immunohistochem Mol Morphol; 2016 Jan; 24(1):20-5. PubMed ID: 26317313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aurora Kinase A Is an Independent Predictor of Invasive Recurrence in Breast Ductal Carcinoma in situ.
    Miligy IM; Toss MS; Gorringe KL; Ellis IO; Green AR; Rakha EA
    Pathobiology; 2022; 89(6):382-392. PubMed ID: 35533650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Collagen (XI) alpha-1 chain is an independent prognostic factor in breast ductal carcinoma in situ.
    Toss MS; Miligy IM; Gorringe KL; Aleskandarany MA; Alkawaz A; Mittal K; Aneja R; Ellis IO; Green AR; Rakha EA
    Mod Pathol; 2019 Oct; 32(10):1460-1472. PubMed ID: 31175327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HER2-Overexpressing Ductal Carcinoma
    O'Keefe TJ; Blair SL; Hosseini A; Harismendy O; Wallace AM
    Cancer Prev Res (Phila); 2020 Sep; 13(9):761-772. PubMed ID: 32493703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical significance of HER2 expression in DCIS.
    Akrida I; Mulita F
    Med Oncol; 2022 Nov; 40(1):16. PubMed ID: 36352293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating the Risk of Upstaging HER2-Positive DCIS to Invasive Breast Cancer.
    Mustafa RE; DeStefano LM; Bahng J; Yoon-Flannery K; Fisher CS; Zhang PJ; Tchou J; Czerniecki BJ; De La Cruz LM
    Ann Surg Oncol; 2017 Oct; 24(10):2999-3003. PubMed ID: 28766212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.